Chemistry: analytical and immunological testing – Cancer
Patent
1995-08-07
1998-08-18
Scheiner, Toni R.
Chemistry: analytical and immunological testing
Cancer
436813, 435 723, G01N 33574
Patent
active
057957851
DESCRIPTION:
BRIEF SUMMARY
BACKGROUND OF THE INVENTION
The given invention relates to medicine or, more precisely, clinical oncology and, in particular, is associated with the means of diagnosis for human malignant tumors, which can find application in mass prophylactic screenings of population.
One of the main problems of clinical oncology lies in the diagnosis of malignant tumors in the initial stage of their development when the existing methods of treatment are most effective. The oncologic science currently disposes of a number of methods for screening diagnosis of malignant neoplasms enabling judgement on the presence or absence of tumor at the time of examination.
In part, prophylactic mammography has gained vast ground, which is carried 15 out with the aim of early diagnosis for malignant neoplasms of the mammary gland in female population (A. G.Holleb. Review of Breast Cancer Screening Guidelines. Cancer Supplement, 1992;69:1911-1912).
A method for cytologic screening of malignant cervical tumors is also known (Guzick D. S. Efficacy for screening for cervical cancer. A review. Am. J.Public Health, 1978;68:125-134.) However, the use of the majority of the known methods for screening diagnosis is directed at identification of tumors in one organ only and during examination other malignant neoplasms can be overlooked.
That is why until now there is a problem of creating a universal method for the diagnosis of malignant tumors meeting the requirements of screening techniques.
A number of researchers hold that the most promising methods in this respect are those based on identification of tumor markers in the host biologic liquids, such as blood, in particular.
Thus, a method for the diagnosis of human malignant tumors is known, which is based on isolation of protein fractions specific for malignant growth in the blood of an individual examined. (Korotkoruchko V. P. Cancer sedimentation reaction in the diagnosis of tumor disease.--Kiev. Naukova dumka.--1967.--80 p.) This protein fraction was isolated by maintaining blood serum in a solution of hydro-chloric acid with subsequent sedimentation of protein with nitric acid and its further dissolution in distilled water. The sediment of blood serum proteins from cancer patients thus formed was not dissolved in contrast to that from healthy individuals.
The reaction result termed cancer sedimentation reaction (CSR) was determined by visual assessment of the protein sediment.
This well-known method is universal and enables identification of various forms and sites of malignant neoplasms. However, it does not possess sufficient specificity, since CSR is often positive in inflammatory and other non-tumor disease. Besides, this method is rather labour consuming (blood serum from the person examined requires preparation) and traumatic (blood for examination is withdrawn from the vein). Therefore, such a method will be of low efficacy for mass prophylactic screenings.
SUMMARY OF THE INVENTION
This invention is based on the task of developing a method for the diagnosis of human malignant tumors, which with the help of an original technique for isolation, in a blood smear from the patient finger predominantly, of certain protein fractions (Calcium-protein complexes) characteristic of malignant growth, would enable increased specificity and sensitivity of the method with a concurrent decrease in its laboriousness and traumatism, which allows, in the final analysis, to apply this method for mass prophylactic screenings for cancer.
The task so posed finds its solution in the fact that in the method for human malignant tumor diagnosis based on identification of blood protein fractions specific for malignant growth, in accordance with the invention, a smear of blood taken predominantly from patient finger is prepared in the process of analysis with consequential layering on top the solution of complexon, standard blood serum and then a developer of Calcium-protein complexes (CPC) and following light exposure, the colour and structure of the stain obtained are compared to those on the standard
REFERENCES:
Schomacker, K. et al. 1992 Nucl. Med. 31: 242-8.
Gibco--BRL. catalog, 1991. pp. 651, 653.
Lavenda, N 1985 Oncology 42(3): 201-204.
Underwood, JCE et al. 1988 J. Pathol. 155: 95-96.
Zvetkova, E. et al. 1979. Folia Haematol. 106(2): 205-223.
Dadoune, J.P. et al. 1991 Cell Tissue Res. 264:167-173.
Galakhin Konstantin Alexandrovich
Novik Matveeevich Anatoly
Suslov Eugene Ivanovich
Vladimirov Vitaly Alexandrovich
Scheiner Toni R.
Zborovky Ilya
LandOfFree
Method for the diagnosis of human malignant tumors does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method for the diagnosis of human malignant tumors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for the diagnosis of human malignant tumors will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1114095